NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

NeuroOne Medical Technologies Corp excels in Q2 2024 performance

NeuroOne Medical Technologies Corp demonstrated strong commercial and financial performance in Q2 2024.
The company's focus on innovation, strategic partnerships, and diverse product development is driving growth.
While facing challenges in capital management and market competition, NeuroOne is well-positioned for future success.
Opportunities in product diversification, market expansion, and fundraising set the stage for continued growth and profitability.

NeuroOne Medical Technologies Corp reports strong Q3 performance and expansion opportunities

NMTC's Q3 2024 performance reflects progress in commercialization and product revenue growth, supported by strategic financing initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to capitalize on distribution agreements and product expansion.
With a focus on innovation and market penetration, NMTC is poised for growth through new FDA applications and leveraging its technological advancements.

NeuroOne Medical Technologies Corp achieves FDA clearance and revenue growth

NeuroOne Medical Technologies Corp made significant strides in product development, securing partnerships, and achieving FDA clearance, positioning the company for growth.
While facing challenges in stock price compliance and market competition, the company's focus on innovation and revenue growth presents opportunities for expansion.
With a strong financial performance in 2024 and revenue growth projections for 2025, NeuroOne is poised to capitalize on market demand and technological advancements.
By diversifying product applications and exploring new partnerships, NeuroOne aims to drive market penetration and establish itself as a key player in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn. , May 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter of fiscal year 2022 ended March 31, 2022.

NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn. , May 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its second quarter of fiscal 2022, ended March 31, 2021, on May 12, 2022 at 4:30 PM Eastern Time.

NeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12

EDEN PRAIRIE, Minn. , April 18, 2022  /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference being held April 19-21, 2022.

NeuroOne® to Present its Disruptive Next-Generation Diagnostic Electrode Technology at the NobleCon18 Investor Conference on April 20, 2022

EDEN PRAIRIE, Minn. , March 30, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that a telephone replay of its investor conference call discussing recent disclosures, held yesterday, will be available through April 11, 2022.

NeuroOne® Investor Call Replay Available Through April 11th

EDEN PRAIRIE, Minn. , March 28, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will host a conference call to discuss recent disclosures tomorrow, March 29, 2022, at 10:00 am Eastern Time.

NeuroOne® to Host Investor Call About Recent Disclosures Tomorrow March 29th at 10:00 am ET

EDEN PRAIRIE, Minn., March 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it is scheduled to attend two investor conferences during the month of March 2022.

NeuroOne to Present its Game-Changing Neuroscientific Technology at the Oppenheimer 32nd Annual Healthcare Conference and 34th Annual ROTH Conference

EDEN PRAIRIE, Minn., March 2, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial bench top, long-term stimulation testing on a novel design of its thin film electrode technology.

NeuroOne® Releases Successful Completion of Long-Term Stimulation Tests for its Novel Thin Film Platform Electrode Technology

NeuroOne Medical Technologies Corporation (NMTC) CEO Dave Rosa on Q1 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Feb. 14, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces its operating results for the first quarter of fiscal year 2022 ended December 31, 2021.

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Feb. 8, 2022  /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology.

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology

EDEN PRAIRIE, Minn., Feb. 2, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its first quarter of fiscal 2022, ended December 31, 2021, on February 14, 2022 at 4:30 PM Eastern Time.

NeuroOne to Host First Quarter Fiscal Year 2022 Earnings Call

EDEN PRAIRIE, Minn., Jan. 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces the appointment of Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs.

NeuroOne Appoints Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs

EDEN PRAIRIE, Minn., Dec. 20, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, was featured on The Medical Alley Podcast, in an episode titled "A Conversation with Dave Rosa, President and CEO, NeuroOne.

NeuroOne Featured on The Medical Alley Podcast: "A Conversation with Dave Rosa, President and CEO, NeuroOne"

NeuroOne Medical Technologies' (NMTC) CEO Dave Rosa on Q4 2021 Earnings Call Transcript

EDEN PRAIRIE, Minn., Dec. 15, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today financial results for the quarter and full fiscal year ended September 30, 2021.

NeuroOne Reports Fourth Fiscal Quarter and Full Fiscal Year 2021 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Dec. 6, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today it will host a conference call to discuss financial results for its fourth quarter and fiscal year ended September 30, 2021, on December 15, 2021, at 9:00 AM Eastern Time.

NeuroOne to Host Fourth Quarter 2021 Earnings Call

NeuroOne is a developer of flexible, minimally invasive, thin film electrodes for cEEG and sEEG recording, and the diagnosis and treatment of neurological conditions. Mayo Clinic is a key development partner and shareholder, and Zimmer Biomet is a strategic development and marketing partner.

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

EDEN PRAIRIE, Minn., Oct. 13, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the pricing of an underwritten registered public offering of 3,750,000 shares of its common stock at a price of $3.20 per share.

NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock

EDEN PRAIRIE, Minn., Sept. 23, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed an animal feasibility study of its combination recording and ablation technology at T3 Labs and Georgia State/Georgia Tech Center for Advanced Brain Imaging in Atlanta Georgia under the guidance of Dr. Robert Gross of Emory University.

NeuroOne® Medical Technologies Corporation Announces Successful Completion of Feasibility Study for Ablation Electrode

EDEN PRAIRIE, Minn., Sept. 9, 2021 /PRNewswire/ -- NeuroOne ®  Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that management will present at the H.C.

NeuroOne to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EDEN PRAIRIE, Minn., Sept. 7, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

NeuroOne® Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo® sEEG Electrode

EDEN PRAIRIE, Minn., Aug. 25, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, was featured on Cheddar News, in a segment titled, "Can This Brain Implant Save Lives?

NeuroOne Featured on Cheddar News (VIDEO): "Can This Brain Implant Save Lives?"

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has executed an agreement with RBC Medical Innovations for a proprietary radiofrequency (RF) generator. The program will develop and manufacture an RF generator for use with NeuroOne's ablation electrode designed to record brain activity and ablate brain tissue using the same electrode.

NeuroOne, RBC Medical Innovations Come Together For Ablation Device Program

EDEN PRAIRIE, Minn., Aug. 23, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that it has executed an agreement with RBC Medical Innovations to develop and manufacture a proprietary radiofrequency (RF) generator for use with NeuroOne's combination recording and ablation electrode that is being designed to both record brain activity and ablate brain tissue using the same electrode.

NeuroOne Announces Strategic Partnership with RBC Medical Innovations for Ablation Program

NeuroOne Medical Technologies' (NMTC) CEO Dave Rosa on Q3 2021 Results - Earnings Call Transcript

News for NeuroOne Medical Technologies Corp Stock (NMTC)